Additional insights


  • Intellectual Property Do’s and Don’ts for Early-Stage Life Sciences Companies,” Life Sciences Leader (February 1, 2022)
  • “Intellectually Smart Devices: Navigating Patent Risks in the Age of Intelligent Inhalers,” Respiratory Drug Delivery Europe 2019 (May 2019)
  • “The Myriad Appeal: Federal Circuit rules that isolated DNA sequences are patent eligible subject matter under § 101,” Lexology (August 2011)
  • “Description proscription? Ariad v. Lilly decision to be reviewed by full court,” Industrial Biotechnology (2009)
  • The Bright Side of Nuclear Winter: Opportunities in the New, New Economy,” (January 2009)
  • “Maximizing IP value in an economic downturn (& beyond) in the life science industry,” Industrial Biotechnology (2009)

Speaking engagements

  • “IPRs During The Pandemic: What Has Been Happening At The PTAB?” Consero IP Management Forum (October 22, 2021)
  • “Maximizing your IP Due Diligence Approach and How the Deal is Structured,” Momentum’s Due Diligence for Life Sciences (August 18, 2021)
  • “A View From The Trenches Of The PTAB: Strategies For Patent Owners (& Patent Applicants),” Consero 2019 Global IP Management Forum (December 2019)
  • “A View from the Tranches of the PTAB: Strategies for Patent Owners,” Consero 2019 Global IP Management Forum (June 2019)
  • “Intellectually Smart Devices: Navigating Patent Risks in the Age of Intelligent Inhalers” Respiratory Drug Delivery Europe 2019 (May 2019)
  • “Managing The Inside-Outside Counsel Working Relationship” Consero 2017 IP Forum for Life Sciences (April 2017)
  • “KnowledgeBridge: A View From The Trenches Of The Most-Active Forum For Patent Validity Challenges – The PTAB” Consero 2017 IP Forum for Life Sciences (April 2017)
  • “IP Perspectives – US and China Webinar Series: Cross-Border Patent Issues in the Life Sciences,” Fish Webinar (April 2017)
  • “Knowledge Bridge: A View From the Trenches of the Most Active Forum for Patent Validity Challenges—the PTAB,” Consero 2016 IP Forum for Life Sciences (December 2016)
  • “Biologics Litigation and IPRs,” Fish Webinar (October 2016)
  • “Three Years Post-AIA: What Have We Learned?,” Consero 2016 Global IP Management Forum (June 2016)
  • “PTAB Adjudication Process: Lessons Learned Over Three Years,” Thomas Jefferson School of Law IP Symposium: Aftershocks of the AIA’s Post-Grant Proceedings: Its Advocates & Critics (April 2016)
  • “Three Years After the AIA: What Have We Learned?,” Consero 2015 IP Forum for Pharmaceuticals and Biotechnology (December 2015)
  • “Advanced Strategies for Life Sciences Companies: IPR and FDA Regulatory Strategy,” Georgia Bio Innovation Summit (November 2015)
  • “Old Dog, New Tricks: Forward-Thinking Trends for the AIA,” Consero 2015 Global IP Management Forum (June 2015)
  • “Foreign Filing Strategies – Considerations in Protecting Your Patents Globally,” Fish Patent Webinar (February 2014)
  • “The Eternal Balancing Act: Protecting Your Global IP And Sticking To Budget,” Consero 2013 IP Pharma Summit (December 2013)
  • “Post-Grant for Practitioners Part IX: Inter Partes Review and the Life Sciences,” Fish Post-Grant Webinar (October 2013)
  • “Maximizing IP Due Diligence to Minimize Risk,” Consero 2013 Intellectual Property Management Forum (June 2013)
  • “First Inventor to File Under AIA,” Minneapolis Patents on Tap Series (March 2013)
  • “America Invents Act: Adapting to the New Rules,” Silicon Valley Life Sciences Series (March 2013)
  • “America Invents Act: Get Ready for the New Rules,” Boston Biotech Series (February 2013)

Media mentions